

Juan Carlos Garc a-Pagan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1932085/publications.pdf>

Version: 2024-02-01

392
papers

38,702
citations

1463

107
h-index

3579

181
g-index

412
all docs

412
docs citations

412
times ranked

15287
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply to: Correspondence on “Predicting portal thrombosis in cirrosis: A prospective study of clinical, ultrasonographic and hemostatic factors” Journal of Hepatology, 2022, 76, 227-228.	3.7	0
2	Budd-Chiari Syndrome: Hepatic Venous Outflow Tract Obstruction. , 2022, , 79-92.		0
3	Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: A case-control study. Hepatology, 2022, 76, 418-428.	7.3	11
4	The Interplay between Pathophysiological Pathways in Early-Onset Severe Preeclampsia Unveiled by Metabolomics. Life, 2022, 12, 86.	2.4	6
5	The Pathophysiology of Portal Vein Thrombosis in Cirrhosis: Getting Deeper into Virchow’s Triad. Journal of Clinical Medicine, 2022, 11, 800.	2.4	20
6	Baveno VII “Renewing consensus in portal hypertension. Journal of Hepatology, 2022, 76, 959-974.	3.7	890
7	Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. Blood Advances, 2022, 6, 4516-4523.	5.2	16
8	The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study. Journal of Thrombosis and Haemostasis, 2022, 20, 2075-2082.	3.8	16
9	Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia. Cardiovascular Drugs and Therapy, 2021, 35, 521-532.	2.6	15
10	Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. Journal of Hepatology, 2021, 74, 89-95.	3.7	25
11	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. Gastroenterology, 2021, 160, 193-205.e10.	1.3	97
12	Reply to: Correspondence on “Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis” Journal of Hepatology, 2021, 74, 252-254.	3.7	0
13	Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. Journal of Hepatology, 2021, 74, 811-818.	3.7	55
14	Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 73, 366-413.	7.3	295
15	Liver Stiffness by Transient Elastography to Detect Porto-Sinusoidal Vascular Liver Disease With Portal Hypertension. Hepatology, 2021, 74, 364-378.	7.3	40
16	Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. Blood, 2021, 137, 1233-1240.	1.4	42
17	Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2021, 121, 867-876.	3.4	28
18	Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics. Scientific Reports, 2021, 11, 3048.	3.3	25

#	ARTICLE	IF	CITATIONS
19	Risk factors of poor prognosis in patients with pyrrolidine alkaloids induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt. <i>Hepatology International</i> , 2021, 15, 568-570.	4.2	2
20	Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline “Update 2021. <i>Endoscopy</i> , 2021, 53, 751-762.	1.8	63
21	Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature. <i>Cancers</i> , 2021, 13, 2688.	3.7	18
22	Treatment of Acute Variceal Bleeding in 2021 “When to Use Transjugular Intrahepatic Portosystemic Shunts?. <i>Clinics in Liver Disease</i> , 2021, 25, 345-356.	2.1	6
23	A simple nomogram identifies patients with refractory ascites with worse outcome after transjugular intrahepatic portosystemic shunt. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e587-e593.	1.6	1
24	Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. <i>JHEP Reports</i> , 2021, 3, 100264.	4.9	35
25	Failure to control variceal bleeding: Definition matters. <i>Journal of Hepatology</i> , 2021, 74, 1491-1492.	3.7	1
26	Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension. <i>Frontiers in Physiology</i> , 2021, 12, 649668.	2.8	4
27	Autoimmune biomarkers in porto “sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology. <i>Liver International</i> , 2021, 41, 2171-2178.	3.9	7
28	TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard “of “Care Therapy. <i>Hepatology</i> , 2021, 74, 2735-2744.	7.3	32
29	Reply. <i>Gastroenterology</i> , 2021, 161, 372-373.	1.3	0
30	Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. <i>Journal of Hepatology</i> , 2021, 75, 1367-1376.	3.7	73
31	Risk of non “tumoural portal vein thrombosis in patients with HCV “induced cirrhosis after sustained virological response. <i>Liver International</i> , 2021, 41, 2954-2964.	3.9	5
32	Management of the major complications of cirrhosis: Beyond guidelines. <i>Journal of Hepatology</i> , 2021, 75, S135-S146.	3.7	20
33	Combination of Model for End “Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding. <i>Hepatology</i> , 2021, 74, 2085-2101.	7.3	25
34	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	3.7	28
35	Proximal Splenic Artery Embolization to Treat Refractory Ascites in a Patient With Cirrhosis. <i>Hepatology</i> , 2021, 74, 3534-3538.	7.3	5
36	Current knowledge and management of portal vein thrombosis in cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 442-453.	3.7	93

#	ARTICLE	IF	CITATIONS
37	Impact of lifestyle interventions targeting physical exercise and caloric intake on cirrhosis regression in rats. American Journal of Physiology - Renal Physiology, 2021, 321, G603-G616.	3.4	2
38	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. JHEP Reports, 2021, 3, 100368.	4.9	3
39	Letter to the Editor: Salvage TIPS in Patients With Cirrhosis With Variceal Bleeding: MELD, Lactates, and "à la Carte" Decision. Hepatology, 2021, 74, 3558-3559.	7.3	0
40	Endoscopic Cyanoacrylate Injection Versus Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial. Hepatology, 2021, 74, 2074-2084.	7.3	49
41	Reply to: "The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites". JHEP Reports, 2021, 3, 100349.	4.9	1
42	Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease. Journal of Hepatology, 2021, 75, 924-934.	3.7	11
43	Spermidine Supplementation Protects the Liver Endothelium from Liver Damage in Mice. Nutrients, 2021, 13, 3700.	4.1	5
44	Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. Hepatology, 2020, 71, 658-669.	7.3	95
45	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 313-327.e6.	4.4	74
46	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology, 2020, 71, 1023-1036.	7.3	112
47	Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort. Journal of Hepatology, 2020, 72, 702-710.	3.7	45
48	Congenital antithrombin deficiency in patients with splanchnic vein thrombosis. Liver International, 2020, 40, 1168-1177.	3.9	10
49	Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?". Journal of Hepatology, 2020, 73, 977-979.	3.7	0
50	Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders. Alimentary Pharmacology and Therapeutics, 2020, 52, 927-928.	3.7	5
51	New Insights into the Pathogenesis, Risk Factors, and Treatment of Portal Vein Thrombosis in Patients with Cirrhosis. Seminars in Thrombosis and Hemostasis, 2020, 46, 673-681.	2.7	16
52	Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. Seminars in Liver Disease, 2020, 40, 240-255.	3.6	46
53	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. Journal of Hepatology, 2020, 73, 1415-1424.	3.7	104
54	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data meta-analysis. Liver International, 2020, 40, 1435-1446.	3.9	35

#	ARTICLE	IF	CITATIONS
55	Budd-Chiari Syndrome: Anticoagulation, TIPS, or Transplant. Current Hepatology Reports, 2020, 19, 197-202.	0.9	1
56	Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. Annals of Hematology, 2020, 99, 791-798.	1.8	17
57	A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. Hepatology, 2020, 72, 1353-1365.	7.3	32
58	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. Journal of Hepatology, 2020, 72, 1140-1150.	3.7	97
59	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. Journal of Hepatology, 2020, 73, 1082-1091.	3.7	112
60	Where does TIPS fit in the management of patients with cirrhosis?. JHEP Reports, 2020, 2, 100122.	4.9	72
61	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. Hepatology, 2019, 69, 282-293.	7.3	144
62	Portal Hypertensive Bleeding. , 2019, , 171-179.e3.		1
63	Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. FASEB Journal, 2019, 33, 11595-11605.	0.5	68
64	The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. Journal of Hepatology, 2019, 71, 942-950.	3.7	61
65	Predicting Heart Failure After TIPS: Still More Questions Than Answers. Hepatology, 2019, 70, 1889-1891.	7.3	3
66	Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease. , 2019, 10, 684.		30
67	Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment—Is It Worth Measuring?. Current Hepatology Reports, 2019, 18, 174-186.	0.9	38
68	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology, 2019, 157, 149-162.	1.3	178
69	Reply:. Hepatology, 2019, 70, 753-754.	7.3	0
70	Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study. Hepatology, 2019, 70, 911-924.	7.3	11
71	Porto-sinusoidal vascular disease: proposal and description of a novel entity. The Lancet Gastroenterology and Hepatology, 2019, 4, 399-411.	8.1	149
72	Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. Journal of Hepatology, 2019, 71, 175-199.	3.7	80

#	ARTICLE	IF	CITATIONS
73	Reply to: “Splenic artery aneurysms, portal hypertension and pregnancy” Journal of Hepatology, 2019, 70, 1026-1027.	3.7	2
74	Budd-Chiari syndrome with short-length stenosis: still room for the angioplasty and wait-and-see strategy. The Lancet Gastroenterology and Hepatology, 2019, 4, 823.	8.1	5
75	Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. Liver International, 2019, 39, 705-713.	3.9	17
76	Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. Journal of Hepatology, 2019, 70, 458-469.	3.7	173
77	Reply. Hepatology, 2019, 69, 1360-1361.	7.3	12
78	Idiopathic Portal Hypertension (Portosinusoidal Disease). , 2018, , 301-308.		0
79	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology, 2018, 154, 1694-1705.e4.	1.3	162
80	Portal vein thrombosis. Current Opinion in Organ Transplantation, 2018, 23, 250-256.	1.6	25
81	Esophageal Stents for Acute Variceal Bleeding: Expanding the Possibilities. Digestive Diseases and Sciences, 2018, 63, 275-276.	2.3	5
82	Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis. Hepatology, 2018, 68, 1508-1518.	7.3	33
83	Reply. Gastroenterology, 2018, 154, 1551-1552.	1.3	0
84	Acute variceal bleeding: risk stratification and management (including TIPS). Hepatology International, 2018, 12, 81-90.	4.2	38
85	Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology, 2018, 67, 1683-1694.	7.3	114
86	Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. Gastroenterology, 2018, 155, 1564-1577.	1.3	97
87	Idiopathic Portal Hypertension. Hepatology, 2018, 68, 2413-2423.	7.3	45
88	Portal Hypertension Reverses Following Successful Antiviral Treatment for HCV: Fact or Fiction?. Current Hepatology Reports, 2018, 17, 209-217.	0.9	4
89	Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome. Journal of Hepatology, 2018, 69, 1242-1249.	3.7	26
90	The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology, 2017, 65, 2031-2044.	7.3	71

#	ARTICLE	IF	CITATIONS
91	Reply. Hepatology, 2017, 65, 2121-2122.	7.3	0
92	Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension. Gastroenterology, 2017, 152, 1358-1365.	1.3	51
93	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Journal of Hepatology, 2017, 67, 501-507.	3.7	50
94	Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies. Scientific Reports, 2017, 7, 3255.	3.3	53
95	Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation. Shock, 2017, 47, 370-377.	2.1	30
96	Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. Hepatology, 2017, 66, 1219-1231.	7.3	80
97	Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats. Liver International, 2017, 37, 1002-1012.	3.9	42
98	Nonendoscopic management of acute esophageal variceal bleeding. Techniques in Gastrointestinal Endoscopy, 2017, 19, 79-83.	0.3	0
99	Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology, 2017, 65, 1293-1305.	7.3	225
100	Risk of bleeding in cirrhotic patients treated with rivaroxaban. Liver International, 2017, 37, 1575-1576.	3.9	1
101	Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. Gastroenterología Y Hepatología (English Edition), 2017, 40, 538-580.	0.1	10
102	Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology, 2017, 153, 1273-1283.e1.	1.3	210
103	The anticoagulant efficacy of rivaroxaban may be attenuated in cirrhotic patients. Liver International, 2017, 37, 1252-1252.	3.9	2
104	Enfermedades vasculares del hígado. Guías Clínicas de la Sociedad Catalana de Digestología y de la Asociación Española para el Estudio del Hígado. Gastroenterología Y Hepatología, 2017, 40, 538-580.	0.5	20
105	Reply to: "Calreticulin mutations and their importance in Budd-Chiari syndrome". Journal of Hepatology, 2017, 67, 1112-1113.	3.7	0
106	Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver International, 2017, 37, 694-699.	3.9	178
107	Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury. Journal of Hepatology, 2017, 66, 86-94.	3.7	84
108	Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology, 2016, 63, 1957-1967.	7.3	174

#	ARTICLE	IF	CITATIONS
109	Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. <i>Hepatology</i> , 2016, 64, 224-231.	7.3	69
110	Early transjugular intrahepatic portosystemic shunt: When, how and in whom?. <i>Gastroenterology</i> Y <i>Hepatology</i> (English Edition), 2016, 39, 472-476.	0.1	0
111	Reply. <i>Hepatology</i> , 2016, 64, 321-322.	7.3	1
112	Metabolomics as a diagnostic tool for idiopathic non-cirrhotic portal hypertension. <i>Liver International</i> , 2016, 36, 1051-1058.	3.9	15
113	Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. <i>Hepatology</i> , 2016, 63, 1640-1650.	7.3	73
114	Nontumoral portal vein thrombosis in patients awaiting liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 352-365.	2.4	99
115	Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy. <i>Scientific Reports</i> , 2016, 6, 22107.	3.3	35
116	Development of hyperdynamic circulation and response to β -blockers in compensated cirrhosis with portal hypertension. <i>Hepatology</i> , 2016, 63, 197-206.	7.3	143
117	Calculating Hepatic Venous Pressure Gradient: Feel Free to Stay Free. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1138-1139.	0.5	10
118	Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. <i>Endoscopy</i> , 2016, 48, 939-948.	1.8	257
119	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <i>Gastroenterology</i> , 2016, 150, 1160-1170.e3.	1.3	232
120	Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. <i>Journal of Hepatology</i> , 2016, 64, 834-842.	3.7	97
121	Transjugular Intrahepatic Portosystemic Shunt for Acute Variceal Bleeding. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 495-505.	2.2	38
122	Impact of anticoagulation on upper gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. <i>Hepatology</i> , 2015, 62, 575-583.	7.3	105
123	The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. <i>Hepatology</i> , 2015, 62, 1584-1592.	7.3	57
124	Prognosis of acute variceal bleeding: Is being on β -blockers an aggravating factor? A short-term survival analysis. <i>Hepatology</i> , 2015, 62, 1840-1846.	7.3	11
125	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2015, 261, e105.	4.2	8
126	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. <i>Hepatology</i> , 2015, 62, 762-772.	7.3	230

#	ARTICLE	IF	CITATIONS
127	Trials and Tribulations: The Prevention of Variceal Rebleeding. <i>Gastroenterology</i> , 2015, 149, 528-531.	1.3	8
128	EASL Recognition Award Recipient 2015. <i>Journal of Hepatology</i> , 2015, 63, 785-786.	3.7	0
129	Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 985-992.	0.4	25
130	Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis. <i>Haematologica</i> , 2015, 100, e226-e228.	3.5	39
131	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1846-1853.e1.	4.4	60
132	Acute Variceal Bleeding. , 2015, , 93-101.		0
133	Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G301-G309.	3.4	40
134	A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures. <i>Liver International</i> , 2015, 35, 695-703.	3.9	18
135	KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. <i>Cut</i> , 2015, 64, 1434-1443.	12.1	159
136	Real-time shear-wave elastography: Applicability, reliability and accuracy for clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2015, 62, 1068-1075.	3.7	183
137	Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2015, 62, 72-74.	3.7	72
138	A novel form of the human manganese superoxide dismutase protects rat and human livers undergoing ischaemia and reperfusion injury. <i>Clinical Science</i> , 2014, 127, 527-537.	4.3	20
139	An overview of current treatment methods for Budd-Chiari syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 147-157.	0.8	1
140	Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. <i>Liver International</i> , 2014, 34, 16-25.	3.9	64
141	Role of gap junctions modulating hepatic vascular tone in cirrhosis. <i>Liver International</i> , 2014, 34, 859-868.	3.9	22
142	A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding. <i>Gastroenterology</i> , 2014, 146, 412-419.e3.	1.3	285
143	Obeticholic acid: A new light in the shadows treating portal hypertension?. <i>Hepatology</i> , 2014, 59, 2072-2073.	7.3	3
144	Management of Gastric Varices. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 919-928.e1.	4.4	127

#	ARTICLE	IF	CITATIONS
145	Liver sinusoidal endothelial dysfunction after LPS administration: A role for inducible-nitric oxide synthase. <i>Journal of Hepatology</i> , 2014, 61, 1321-1327.	3.7	58
146	Can we identify failure to control acute variceal bleeding?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 705-706.	17.8	0
147	Transjugular Liver Biopsy. <i>Clinics in Liver Disease</i> , 2014, 18, 767-778.	2.1	32
148	Endoscopic Hemostasis in Acute Esophageal Variceal Bleeding. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 795-806.	2.2	7
149	Thromboprophylaxis with heparin in hospitalized patients with cirrhosis: friend or foe. <i>Liver International</i> , 2014, 34, 971-973.	3.9	3
150	Stroke Volume Response to Liver Graft Reperfusion Stress in Cirrhotic Patients. <i>World Journal of Surgery</i> , 2014, 38, 927-935.	1.6	9
151	Idiopathic portal hypertension: Natural history and long-term outcome. <i>Hepatology</i> , 2014, 59, 2276-2285.	7.3	132
152	A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2014, 146, 1231-1239.e6.	1.3	353
153	Imaging in clinical decision-making for portal vein thrombosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 308-316.	17.8	64
154	Unexpected disappearance of portal cavernoma on long-term anticoagulation. <i>Journal of Hepatology</i> , 2014, 61, 446-448.	3.7	12
155	Inflammation and portal hypertension – The undiscovered country. <i>Journal of Hepatology</i> , 2014, 61, 155-163.	3.7	107
156	Lack of Correlation Between Preoperative and Intraoperative Liver Hemodynamics. <i>Transplantation</i> , 2014, 97, 116-121.	1.0	2
157	TIPS: Primary Therapy or Rescue in Treatment of Acute Variceal Hemorrhage. , 2014, , 163-169.		0
158	Use of early-TIPS for high-risk variceal bleeding: Results of a post-RCT surveillance study. <i>Journal of Hepatology</i> , 2013, 58, 45-50.	3.7	259
159	Variceal and other portal hypertension related bleeding. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 649-664.	2.4	54
160	Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats. <i>Hepatology</i> , 2013, 58, 1424-1435.	7.3	37
161	Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. <i>Hepatology</i> , 2013, 58, 1742-1756.	7.3	87
162	The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial – stellate cell deactivation induced by statins. <i>Journal of Hepatology</i> , 2013, 58, 98-103.	3.7	180

#	ARTICLE	IF	CITATIONS
163	Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. <i>Gut</i> , 2013, 62, 452-460.	12.1	167
164	Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. <i>Journal of Hepatology</i> , 2013, 58, 1140-1146.	3.7	60
165	Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl ₄ -cirrhotic rats. <i>Journal of Hepatology</i> , 2013, 58, 240-246.	3.7	61
166	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 103-104.	4.4	0
167	Reply. <i>Gastroenterology</i> , 2013, 144, 1153-1154.	1.3	0
168	Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 102-111.e1.	1.3	437
169	Metabolomics Discloses Potential Biomarkers for the Noninvasive Diagnosis of Idiopathic Portal Hypertension. <i>American Journal of Gastroenterology</i> , 2013, 108, 926-932.	0.4	28
170	Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. <i>Hepatology</i> , 2013, 57, 1172-1181.	7.3	84
171	Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: A multicenter survey on safety and efficacy. <i>Hepatology</i> , 2013, 57, 2448-2457.	7.3	217
172	Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. <i>Journal of Hepatology</i> , 2013, 58, 904-910.	3.7	117
173	Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. <i>Journal of Hepatology</i> , 2013, 59, 717-722.	3.7	17
174	Anticoagulation in cirrhosis: Ready to set or wait!. <i>Hepatology</i> , 2013, 58, 1175-1176.	7.3	5
175	Good long-term outcome of Budd-Chiari syndrome with a step-wise management. <i>Hepatology</i> , 2013, 57, 1962-1968.	7.3	237
176	Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, G496-G502.	3.4	19
177	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study. <i>Liver Transplantation</i> , 2013, 19, 450-456.	2.4	8
178	Cardiovascular Risk Factors and Systemic Endothelial Function in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2013, 108, 75-82.	0.4	27
179	Fibrinogen β^3 and variation in fibrinogen gamma genes in the etiology of portal vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2013, 109, 558-560.	3.4	6
180	Effect of Meal Ingestion on Liver Stiffness in Patients with Cirrhosis and Portal Hypertension. <i>PLoS ONE</i> , 2013, 8, e58742.	2.5	110

#	ARTICLE	IF	CITATIONS
181	Insulin resistance in patients with cirrhosis and portal hypertension. American Journal of Physiology - Renal Physiology, 2012, 302, G1458-G1465.	3.4	23
182	Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. American Journal of Physiology - Renal Physiology, 2012, 302, G1191-G1198.	3.4	36
183	Acute Variceal Bleeding. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 46-54.	2.1	62
184	Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. American Journal of Clinical Nutrition, 2012, 96, 584-590.	4.7	50
185	Management of an acute variceal bleeding episode. Clinical Liver Disease, 2012, 1, 151-154.	2.1	4
186	Hypercoagulability in Patients With Chronic Noncirrhotic Portal Vein Thrombosis. Clinical Gastroenterology and Hepatology, 2012, 10, 72-78.	4.4	36
187	Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis. Clinical Gastroenterology and Hepatology, 2012, 10, 776-783.	4.4	407
188	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. Journal of Hepatology, 2012, 56, 103-108.	3.7	142
189	PPAR α activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. Journal of Hepatology, 2012, 56, 1033-1039.	3.7	73
190	Functional aspects on the pathophysiology of portal hypertension in cirrhosis. Journal of Hepatology, 2012, 57, 458-461.	3.7	219
191	Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension. Journal of Cellular and Molecular Medicine, 2012, 16, 2017-2021.	3.6	0
192	Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats. Journal of Cellular and Molecular Medicine, 2012, 16, 2461-2470.	3.6	28
193	Microparticles and Paracrine Signaling in Portal Hypertension: Crucial Conversations or Idle Chat?. Gastroenterology, 2012, 143, 22-25.	1.3	3
194	Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Digestive and Liver Disease, 2012, 44, 855-860.	0.9	113
195	Patients Whose First Episode of Bleeding Occurs While Taking a β_2 -Blocker Have High Long-term Risks of Rebleeding and Death. Clinical Gastroenterology and Hepatology, 2012, 10, 670-676.	4.4	26
196	Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLD. PLoS ONE, 2012, 7, e32785.	2.5	180
197	Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis. European Journal of Clinical Pharmacology, 2012, 68, 533-541.	1.9	19
198	Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers. Hepatology, 2012, 55, 921-930.	7.3	94

#	ARTICLE	IF	CITATIONS
199	The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood, 2011, 117, 3968-3973.	1.4	43
200	Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. Journal of Hepatology, 2011, 54, 660-665.	3.7	40
201	Serum bilirubin and platelet count: A simple predictive model for survival in patients with refractory ascites treated by TIPS. Journal of Hepatology, 2011, 54, 901-907.	3.7	94
202	Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd-Chiari syndrome. Journal of Hepatology, 2011, 54, 908-914.	3.7	12
203	Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis. Journal of Hepatology, 2011, 55, 307-314.	3.7	43
204	Insulin resistance and liver microcirculation in a rat model of early NAFLD. Journal of Hepatology, 2011, 55, 1095-1102.	3.7	64
205	Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology, 2011, 54, 555-561.	7.3	240
206	Idiopathic noncirrhotic portal hypertension. Hepatology, 2011, 54, 1071-1081.	7.3	248
207	Portal cholangiopathy: radiological classification and natural history. Gut, 2011, 60, 853-860.	12.1	88
208	Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut, 2011, 60, 517-524.	12.1	113
209	Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut, 2011, 60, 1133-1138.	12.1	141
210	The Treatment and Prevention of Variceal Bleeding. , 2011, , 477-500.		0
211	Budd-Chiari Syndrome. , 2011, , 197-211.		0
212	Early use of TIPS in patients with cirrhosis and variceal bleeding. Annals of Internal Medicine, 2010, 153, JC5.	3.9	4
213	Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood, 2010, 115, 388-395.	1.4	43
214	Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology, 2010, 51, 210-218.	7.3	458
215	Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical-hemodynamic correlation study. Hepatology, 2010, 51, 2108-2116.	7.3	74
216	Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology, 2010, 52, 2044-2052.	7.3	180

#	ARTICLE	IF	CITATIONS
217	Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transplantation, 2010, 16, 348-356.	2.4	65
218	Idiopathic Noncirrhotic Portal Hypertension in HIV-Infected Patients. Clinical Infectious Diseases, 2010, 50, 127-128.	5.8	6
219	Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding. New England Journal of Medicine, 2010, 362, 2370-2379.	27.0	1,075
220	NCX-1000, a Nitric Oxide-Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study. American Journal of Gastroenterology, 2010, 105, 1094-1101.	0.4	40
221	A Specialized, Nurse-Run Titration Clinic: A Feasible Option for Optimizing β_2 -Blockade in Non-Clinical Trial Patients. American Journal of Gastroenterology, 2010, 105, 1917-1921.	0.4	13
222	Refractory Acute Variceal Bleeding: What to Do Next?. Clinics in Liver Disease, 2010, 14, 297-305.	2.1	30
223	Serum Fibrosis Markers Identify Patients With Mild and Progressive Hepatitis C Recurrence After Liver Transplantation. Gastroenterology, 2010, 138, 147-158.e1.	1.3	68
224	Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. Journal of Hepatology, 2010, 52, 846-853.	3.7	114
225	Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. Journal of Hepatology, 2010, 53, 273-282.	3.7	112
226	Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension. Journal of Hepatology, 2010, 53, 558-567.	3.7	178
227	Idiopathic Portal Hypertension in Patients With HIV Infection Treated With Highly Active Antiretroviral Therapy. American Journal of Gastroenterology, 2009, 104, 1707-1714.	0.4	85
228	Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. Gut, 2009, 58, 118-125.	12.1	67
229	Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut, 2009, 58, 1144-1150.	12.1	98
230	Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. Journal of Hepatology, 2009, 50, 923-928.	3.7	340
231	Pregnancy in women with known and treated Budd-Chiari syndrome: Maternal and fetal outcomes. Journal of Hepatology, 2009, 51, 47-54.	3.7	85
232	Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. Journal of Hepatology, 2009, 51, 279-287.	3.7	116
233	Portal vein thrombosis: A predictable milestone in cirrhosis?. Journal of Hepatology, 2009, 51, 632-634.	3.7	136
234	Paroxysmal nocturnal hemoglobinuria in Budd-Chiari Syndrome: Findings from a cohort study. Journal of Hepatology, 2009, 51, 696-706.	3.7	98

#	ARTICLE	IF	CITATIONS
235	Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial. <i>Gastroenterology</i> , 2009, 136, 1651-1658.	1.3	372
236	Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2009, 136, 1639-1650.	1.3	197
237	The clinical use of HVPG measurements in chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 573-582.	17.8	576
238	Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 689-695.	4.4	215
239	Etiology, Management, and Outcome of the Budd-Chiari Syndrome. <i>Annals of Internal Medicine</i> , 2009, 151, 167.	3.9	422
240	Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. <i>Hepatology</i> , 2008, 47, 153-159.	7.3	111
241	Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability. <i>Hepatology</i> , 2008, 47, 1248-1256.	7.3	118
242	The management of portal hypertension: Rational basis, available treatments and future options. <i>Journal of Hepatology</i> , 2008, 48, S68-S92.	3.7	248
243	Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis. <i>Liver International</i> , 2008, 28, 566-573.	3.9	6
244	Review article: the modern management of portal hypertension – primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 178-186.	3.7	66
245	Primary prophylaxis of esophageal variceal bleeding in cirrhosis. <i>Gastroenterologie Clinique Et Biologique</i> , 2008, 32, 532-540.	0.9	9
246	TIPS for Budd-Chiari Syndrome: Long-Term Results and Prognostics Factors in 124 Patients. <i>Gastroenterology</i> , 2008, 135, 808-815.	1.3	319
247	Prevention of recurrent variceal bleeding. <i>Digestive and Liver Disease</i> , 2008, 40, 337-342.	0.9	10
248	A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 2747-2756.	0.4	268
249	The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. <i>Blood</i> , 2008, 111, 4922-4929.	1.4	319
250	Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. <i>Journal of Hepatology</i> , 2008, 48, 61-67.	3.7	61
251	Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. <i>Journal of Hepatology</i> , 2008, 48, 229-236.	3.7	284
252	Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats. <i>Journal of Hepatology</i> , 2008, 49, 192-197.	3.7	39

#	ARTICLE	IF	CITATIONS
253	Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. <i>Hepatology</i> , 2008, 47, 1604-1614.	7.3	266
254	Portal Hypertension-Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1412-1417.	4.4	175
255	Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2008, 103, 1159-1167.	0.4	131
256	Portal Hypertension and Gastrointestinal Bleeding. <i>Seminars in Liver Disease</i> , 2008, 28, 003-025.	3.6	114
257	Extrahepatic Portal Vein Thrombosis. <i>Seminars in Liver Disease</i> , 2008, 28, 282-292.	3.6	115
258	NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats. <i>Gut</i> , 2007, 56, 560-564.	12.1	52
259	Is it necessary to endoscopically screen all patients with hepatitis C and advanced fibrosis for esophageal varices?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 370-371.	1.7	0
260	Potential role of antioxidants in the treatment of portal hypertension. <i>Journal of Hepatology</i> , 2007, 46, 193-197.	3.7	27
261	Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. <i>Journal of Hepatology</i> , 2007, 46, 1040-1046.	3.7	203
262	Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. <i>Journal of Hepatology</i> , 2007, 47, 220-227.	3.7	100
263	Efficacy of Antiviral Therapy on Hepatitis C Recurrence After Liver Transplantation: A Randomized Controlled Study. <i>Gastroenterology</i> , 2007, 132, 1746-1756.	1.3	332
264	Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis. <i>Gastroenterology</i> , 2007, 133, 481-488.	1.3	926
265	Current concepts on the pathophysiology of portal hypertension. <i>Annals of Hepatology</i> , 2007, 6, 28-36.	1.5	69
266	Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. <i>Hepatology</i> , 2007, 46, 1208-1217.	7.3	166
267	Noninvasive tests in the post-liver transplantation setting. <i>Liver Transplantation</i> , 2007, 13, 628-629.	2.4	1
268	Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review. <i>Gastroenterology</i> , 2006, 131, 1611-1624.	1.3	435
269	Sonography of Budd-Chiari Syndrome. <i>American Journal of Roentgenology</i> , 2006, 187, W33-W41.	2.2	67
270	Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. <i>Journal of Hepatology</i> , 2006, 44, 1033-1039.	3.7	76

#	ARTICLE	IF	CITATIONS
271	Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension. <i>Journal of Hepatology</i> , 2006, 44, 1040-1045.	3.7	6
272	Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis. <i>American Journal of Gastroenterology</i> , 2006, 101, 506-512.	0.4	228
273	Animal models of portal hypertension. <i>World Journal of Gastroenterology</i> , 2006, 12, 6577.	3.3	110
274	Feasibility and Safety of Pancreatic Islet Transplantation in the Liver by Portal Vein Catheterization using the Transjugular Route. <i>Transplantation</i> , 2006, 81, 1220-1221.	1.0	8
275	Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. <i>Hepatology</i> , 2006, 43, 27-33.	7.3	39
276	Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. <i>Hepatology</i> , 2006, 43, 34-41.	7.3	31
277	Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 2006, 43, 485-491.	7.3	106
278	Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. <i>Hepatology</i> , 2006, 43, 492-499.	7.3	282
279	Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. <i>Hepatology</i> , 2006, 43, 707-714.	7.3	113
280	The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. <i>Hepatology</i> , 2006, 44, 44-52.	7.3	103
281	Measurement of Portal Pressure and Its Role in the Management of Chronic Liver Disease. <i>Seminars in Liver Disease</i> , 2006, 26, 348-362.	3.6	182
282	Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD.. <i>Blood</i> , 2006, 108, 377-377.	1.4	8
283	Impact of prior portosystemic shunt procedures on outcome of liver transplantation. <i>Surgery</i> , 2005, 137, 620-625.	1.9	21
284	Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 288, G763-G770.	3.4	65
285	Endoscopic band ligation in the treatment of portal hypertension. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 526-535.	1.7	130
286	Utility of Color Doppler Ultrasonography Predicting TIPS Dysfunction. <i>American Journal of Gastroenterology</i> , 2005, 100, 2696-2701.	0.4	49
287	Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis. <i>New England Journal of Medicine</i> , 2005, 353, 2254-2261.	27.0	952
288	Increased Hepatic Resistance. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S131-S137.	2.2	55

#	ARTICLE	IF	CITATIONS
289	Portal Hypertension Secondary to Myelofibrosis: A Study of Three Cases. American Journal of Gastroenterology, 2005, 100, 2355-2358.	0.4	30
290	Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. Journal of Hepatology, 2005, 43, 98-103.	3.7	196
291	Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World Journal of Gastroenterology, 2005, 11, 6858.	3.3	66
292	The Budd-Chiari Syndrome. New England Journal of Medicine, 2004, 350, 1906-1908.	27.0	3
293	Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. British Journal of Haematology, 2004, 124, 329-335.	2.5	22
294	Monitoring of HVPG during pharmacological therapy: Evidence in favor of the prognostic value of a 20% reduction. Hepatology, 2004, 39, 1746-1747.	7.3	9
295	PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology, 2004, 40, 1197-1202.	7.3	142
296	Improved clinical outcome using polytetrafluoroethylene-coated stents for tips: Results of a randomized study. Gastroenterology, 2004, 126, 469-475.	1.3	468
297	Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology, 2004, 126, 886-894.	1.3	236
298	Endotipsitis: an emerging prosthetic-related infection in patients with portal hypertension. Diagnostic Microbiology and Infectious Disease, 2004, 49, 77-82.	1.8	32
299	Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators (J Hepatol 1985; 1: 325-337). Journal of Hepatology, 2004, 40, 887-890.	3.7	10
300	Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. Journal of Hepatology, 2004, 41, 384-390.	3.7	141
301	What else we need. , 2004, , 349-360.		1
302	Enhanced release of vasoconstrictors. , 2004, , 89-96.		0
303	Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology, 2003, 37, 378-384.	7.3	78
304	Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology, 2003, 37, 902-908.	7.3	456
305	Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT. Hepatology, 2003, 37, 1260-1266.	7.3	149
306	Budd-Chiari syndrome: a review by an expert panel. Journal of Hepatology, 2003, 38, 364-371.	3.7	446

#	ARTICLE	IF	CITATIONS
307	Prevention of variceal rebleeding. Lancet, The, 2003, 361, 952-954.	13.7	398
308	Prevention of variceal rebleeding. Lancet, The, 2003, 361, 2245.	13.7	2
309	Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. Journal of Hepatology, 2003, 39, 515-521.	3.7	68
310	Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction. Gut, 2003, 52, 130-133.	12.1	22
311	Sonography of the Caudate Vein: Value in Diagnosing Budd-Chiari Syndrome. American Journal of Roentgenology, 2003, 181, 1641-1645.	2.2	63
312	Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?. Gut, 2002, 50, 425-427.	12.1	108
313	Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. Journal of Hepatology, 2002, 36, 356-361.	3.7	39
314	5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: A possible role of cysteinyl-leukotrienes. Gastroenterology, 2002, 122, 387-393.	1.3	96
315	Non-selective beta-blockers in the prevention of first variceal bleeding. Is there any definite alternative?. Journal of Hepatology, 2002, 37, 393-395.	3.7	7
316	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology, 2002, 36, 1367-1373.	7.3	121
317	Nitric oxide and portal hypertension. Metabolic Brain Disease, 2002, 17, 311-324.	2.9	29
318	TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology, 2002, 35, 132-139.	7.3	190
319	TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial. Hepatology, 2002, 35, 385-392.	7.3	195
320	Increasing intra-abdominal pressure increases pressure, volume, and wall tension in esophageal varices. Hepatology, 2002, 36, 936-940.	7.3	46
321	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology, 2002, 36, 1367-1373.	7.3	113
322	Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology, 2001, 120, 161-169.	1.3	186
323	Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology, 2001, 121, 382-388.	1.3	159
324	ASSESSMENT OF PORTAL HYPERTENSION IN HUMANS. Clinics in Liver Disease, 2001, 5, 575-589.	2.1	15

#	ARTICLE	IF	CITATIONS
325	Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive β_2 -blockers. Gastroenterology, 2001, 121, 908-914.	1.3	94
326	Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd-Chiari patients. Liver Transplantation, 2001, 7, 649-651.	2.4	16
327	Budd-Chiari Syndrome Secondary to Antiphospholipid Syndrome. Medicine (United States), 2001, 80, 345-354.	1.0	95
328	Ascites after liver transplantation. Liver Transplantation, 2000, 6, 157-162.	2.4	37
329	Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology, 2000, 31, 1061-1067.	7.3	158
330	CO ₂ wedged hepatic venography in the evaluation of portal hypertension. Gut, 2000, 46, 856-860.	12.1	43
331	Ascites after liver transplantation. Liver Transplantation, 2000, 6, 157-162.	2.4	24
332	Complications of cirrhosis. I. Portal hypertension. Journal of Hepatology, 2000, 32, 141-156.	3.7	416
333	Influence of Pharmacological Agents on Portal Hemodynamics: Basis for Its Use in the Treatment of Portal Hypertension. Seminars in Liver Disease, 1999, 19, 427-438.	3.6	92
334	Effects of end-to-side portacaval shunt and distal splenorenal shunt on systemic and pulmonary haemodynamics in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 1112-1118.	2.8	7
335	Carvedilol, a new nonselective beta-blocker with intrinsic anti- α_1 -adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology, 1999, 30, 79-83.	7.3	158
336	Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology, 1999, 30, 1393-1397.	7.3	186
337	Hyperkinetic circulation and decreased sensitivity to vasoconstrictors following portacaval shunt in the rat. Effects of chronic nitric oxide inhibition. Journal of Hepatology, 1999, 31, 719-724.	3.7	13
338	Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology, 1999, 117, 626-631.	1.3	435
339	PATTERNS OF VASOREGULATORY GENE EXPRESSION IN THE LIVER RESPONSE TO ISCHEMIA/REPERFUSION AND ENDOTOXEMIA. Shock, 1999, 11, 175-179.	2.1	79
340	ISCHEMIA/REPERFUSION INDUCES AN INCREASE IN THE HEPATIC PORTAL VASOCONSTRICTIVE RESPONSE TO ENDOTHELIN-1. Shock, 1999, 11, 325-329.	2.1	34
341	Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology, 1998, 28, 416-422.	7.3	374
342	Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis. Hepatology, 1998, 28, 677-682.	7.3	69

#	ARTICLE	IF	CITATIONS
343	Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. <i>Gastroenterology</i> , 1998, 115, 116-123.	1.3	108
344	Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings. <i>Gastroenterology</i> , 1998, 114, 1296-1303.	1.3	431
345	Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients. <i>Journal of Hepatology</i> , 1998, 29, 789-795.	3.7	38
346	The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices. <i>Gastroenterology</i> , 1997, 112, 2012-2016.	1.3	70
347	Endoscopic assessment of variceal volume and wall tension in cirrhotic patients: Effects of pharmacological therapy. <i>Gastroenterology</i> , 1997, 113, 1640-1646.	1.3	68
348	Platelet cytosolic calcium concentration in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 1997, 27, 824-829.	3.7	4
349	Time profile of the haemodynamic effects of terlipressin in portal hypertension. <i>Journal of Hepatology</i> , 1997, 26, 621-627.	3.7	117
350	Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. <i>Gastroenterology</i> , 1997, 112, 1284-1289.	1.3	117
351	5 Pharmacological prevention of variceal bleeding. New developments. <i>Bailliere's Clinical Gastroenterology</i> , 1997, 11, 271-287.	0.9	6
352	Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: Influence in nitric oxide biosynthesis. <i>Gastroenterology</i> , 1996, 110, 1529-1535.	1.3	98
353	Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. <i>Gastroenterology</i> , 1996, 111, 1300-1306.	1.3	148
354	Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis. <i>Journal of Hepatology</i> , 1996, 24, 423-429.	3.7	46
355	Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis. <i>Journal of Hepatology</i> , 1996, 24, 430-435.	3.7	11
356	Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. <i>Gastroenterology</i> , 1996, 111, 1018-1022.	1.3	838
357	A prospective randomized trial of heater probe thermocoagulation versus injection therapy in peptic ulcer hemorrhage. <i>Gastrointestinal Endoscopy</i> , 1996, 43, 117-120.	1.0	67
358	Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. <i>Hepatology</i> , 1995, 22, 753-758.	7.3	90
359	Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. <i>Gastroenterology</i> , 1995, 108, 1487-1495.	1.3	127
360	Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis*1. <i>Hepatology</i> , 1995, 21, 83-88.	7.3	5

#	ARTICLE	IF	CITATIONS
361	Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. <i>Lancet, The</i> , 1995, 346, 1056-1059.	13.7	569
362	Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double-blind hemodynamic investigation*1. <i>Hepatology</i> , 1995, 22, 106-111.	7.3	6
363	Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis*1. <i>Hepatology</i> , 1995, 22, 753-758.	7.3	8
364	Circadian variations of portal pressure and variceal hemorrhage in patients with cirrhosis. <i>Hepatology</i> , 1994, 19, 595-601.	7.3	82
365	Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. <i>Hepatology</i> , 1994, 19, 1095-1099.	7.3	111
366	Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. <i>Hepatology</i> , 1994, 20, 30-33.	7.3	55
367	Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: Long-term hemodynamic and renal effects. <i>Hepatology</i> , 1994, 20, 1502-1508.	7.3	67
368	Nicardipine increases hepatic blood flow and the hepatic clearance of indocyanine green in patients with cirrhosis. <i>Journal of Hepatology</i> , 1994, 20, 792-796.	3.7	18
369	Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites*1. <i>Hepatology</i> , 1994, 20, 30-33.	7.3	66
370	Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis*1, *2. <i>Hepatology</i> , 1994, 19, 1095-1099.	7.3	25
371	Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. <i>Hepatology</i> , 1993, 17, 213-218.	7.3	41
372	Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. <i>Hepatology</i> , 1993, 17, 355-360.	7.3	183
373	Effects of ritanserlin, a selective and specific 5 ₂ -serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. <i>Hepatology</i> , 1993, 18, 389-393.	7.3	32
374	Reduction of variceal pressure by propranolol: Comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. <i>Hepatology</i> , 1993, 18, 1082-1089.	7.3	71
375	New approaches in the pharmacologic treatment of portal hypertension. <i>Journal of Hepatology</i> , 1993, 17, S41-S45.	3.7	22
376	Hemodynamic effects of acute changes in intra-abdominal pressure in patients with cirrhosis. <i>Gastroenterology</i> , 1993, 104, 222-227.	1.3	117
377	Effects of ritanserlin, a selective and specific 5 ₂ -serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. <i>Hepatology</i> , 1993, 18, 389-393.	7.3	5
378	Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy*1. <i>Hepatology</i> , 1993, 17, 213-218.	7.3	50

#	ARTICLE	IF	CITATIONS
379	Portal hypertension in acute liver failure.. Gut, 1992, 33, 965-968.	12.1	55
380	Lymphocyte β_2 -adrenoceptors and plasma catecholamines in patients with cirrhosis. Gastroenterology, 1992, 102, 2015-2023.	1.3	26
381	Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology, 1992, 102, 2114-2119.	1.3	59
382	Hepatic, splanchnic and systemic haemodynamic abnormalities in portal hypertension. Bailliere's Clinical Gastroenterology, 1992, 6, 425-436.	0.9	19
383	Long-term effects of distal splenorenal shunt on hepatic hemodynamics and liver function in patients with cirrhosis: Importance of reversal of portal blood flow. Hepatology, 1992, 15, 616-622.	7.3	24
384	PATHOPHYSIOLOGY OF PORTAL HYPERTENSION. Gastroenterology Clinics of North America, 1992, 21, 1-14.	2.2	221
385	Effects of molsidomine, a long acting venous dilator, on portal hypertension. Journal of Hepatology, 1991, 13, 179-186.	3.7	15
386	Propranolol Compared with Propranolol plus Isosorbide-5-Mononitrate for Portal Hypertension in Cirrhosis. Annals of Internal Medicine, 1991, 114, 869-873.	3.9	237
387	Glucagon hinders the effects of somatostatin on portal hypertension. Gastroenterology, 1991, 101, 1710-1715.	1.3	89
388	Hepatic fibrin-ring granulomas in a patient with hepatitis A. Gastroenterology, 1991, 100, 268-270.	1.3	42
389	Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology, 1990, 11, 230-238.	7.3	172
390	Effects of Propranolol on Arterial Oxygenation and Oxygen Transport to Tissues in Patients with Cirrhosis. The American Review of Respiratory Disease, 1990, 142, 306-310.	2.9	44
391	Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. Journal of Hepatology, 1990, 11, 189-195.	3.7	96
392	Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: Comparison with the effects on portal pressure. Hepatology, 1988, 8, 861-865.	7.3	78